Results 51 to 60 of about 41,957 (165)

Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions

Frontiers in Immunology, 2020
Elizabeth Krieger, Amir Ahmed Toor
doaj   +1 more source

Second allogeneic transplants in children: twelve years of experience

Biomédica: revista del Instituto Nacional de Salud
Introduction. A second hematopoietic stem cell transplant is required when the first transplant fails, usually due to relapse or graft failure, and is associated with increased morbidity and mortality.
Alexis Antonio Franco, Eliana Manzi Tarapues, Sergio Camilo Cabrera Salcedo, Diana Marcela Muñoz Caluce, Diego Medina   +4 more
doaj   +1 more source

Graft-vs-Host Disease in a Liver Transplant Patient With COVID-19 Infection. [PDF]

ACG Case Rep J, 2023
Kiparizoska S, Nguyen V, Rangnekar AS.
europepmc   +1 more source

Chronic graft-vs-host disease: Current understanding of disease and treatment landscape. [PDF]

J Manag Care Spec Pharm, 2022
Flavin B.
europepmc   +1 more source

AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease. [PDF]

Mol Ther Methods Clin Dev, 2023
Nilles JP, Roberts D, Salmon JH, Song L, O'Dea C, Marjoram LT, Bower JJ, Hirsch ML, Gilger BC.   +8 more
europepmc   +1 more source

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner. [PDF]

J Adv Pract Oncol, 2023
Kachur E, Patel JN, Morse AL, Moore DC, Arnall JR.   +4 more
europepmc   +1 more source

Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. [PDF]

Front Immunol
Lu N, Zheng Y, Guo W, Zheng X, Feng D, Cao Y, Zhang R, Zhai W, Yang D, Wei J, He Y, Pang A, Feng S, Han M, Jiang E.   +14 more
europepmc   +1 more source

Case Report: Successful treatment of steroid-refractory graft-vs.-host disease following bilateral lung transplantation. [PDF]

Front Transplant
McCormick BJ, Rusanov V, Tao Z, Kaleekal T, Wille K, Espinoza-Gutarra MR.   +5 more
europepmc   +1 more source

Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. [PDF]

Cell Rep Med, 2023
Bailey C, Wei Y, Yan J, Huang D, Zhang P, Qi C, Lazarski C, Su J, Tang F, Wong CS, Zheng P, Liu Y, Liu Y, Wang Y.   +13 more
europepmc   +1 more source

Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response. [PDF]

J Cell Mol Med, 2023
Martinez-Sanchez J, Palomo M, Pedraza A, Moreno-Castaño AB, Torramade-Moix S, Rovira M, Salas MQ, Cid J, Escolar G, Penack O, Carreras E, Diaz-Ricart M.   +11 more
europepmc   +1 more source